Commissioner McClellan Will Monitor Staff Morale; CBER’s Siegel Departs
This article was originally published in The Gray Sheet
Executive Summary
CBER Office of Therapeutics Review & Research Director Jay Siegel, MD, is the first high-level departure from the agency since the announcement of the CBER/CDER reorganization